女子尿道症候群症例での尿中インターロイキン6, インターロイキン8の測定

Abstract

21例の女子尿道症候群症例の尿中IL-6, IL-8の測定を行い, インターロイキンの検出率の違いや抗菌剤治療前後での変化について推計学的検討を加えた.これら女子尿道症候群症例中1例にIL-6を, 8例にIL-8が検出され, その値は41.1pg/mgCr, 13.3～560pg/mgCr(平均108.7pg/mgCr).IL-6やIL-8が検出された9症例に対し, スパルフロキサシン 100mgを服用させ, 自覚症状を調べたところ, インターロイキンは測定されなくなり7症例では自覚症状の改善がみられた.残り2名にインターロイキンが検出されたが, うち1症例に症状の改善がみられた

Interleukin-6 (IL-6) and interleukin-8 (IL-8) are important mediators of an inflammatory response. We measured creatinine-collected urinary levels of IL-6 and IL-8 by an enzyme-linked immunosorbent assay in 21 women with urethritis syndrome as well as 20 age-matched healthy women. Urine samples were collected before treatment and after 7 or 14 days of oral administration of sparfloxacin (100 mg once daily). Urinary IL-6 level was elevated in a patient with urethritis syndrome (41.1 pg/mgCr), while urinary IL-8 levels were elevated in 8 (range 13.3 to 560 pg/mgCr). On the other hand, none of the healthy controls showed any detectable urinary level of IL-6 and IL-8. Of the 9 patients with elevated urinary IL-6 or IL-8, symptomatic improvement was obtained after chemotherapy in 8 and urinary interleukins became undetectable in 7. Urinary IL-6 and IL-8 seem to have some role in the induction of urinary symptoms.